Cargando…
Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518335/ https://www.ncbi.nlm.nih.gov/pubmed/18544793 http://dx.doi.org/10.2337/dc07-2217 |
_version_ | 1782158559430049792 |
---|---|
author | Vesterhus, Mette Ræder, Helge Aurlien, Harald Gjesdal, Clara G. Bredrup, Cecilie Holm, Pål I. Molven, Anders Bindoff, Laurence Berstad, Arnold Njølstad, Pål R. |
author_facet | Vesterhus, Mette Ræder, Helge Aurlien, Harald Gjesdal, Clara G. Bredrup, Cecilie Holm, Pål I. Molven, Anders Bindoff, Laurence Berstad, Arnold Njølstad, Pål R. |
author_sort | Vesterhus, Mette |
collection | PubMed |
description | OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL gene mutation, exocrine deficiency, and diabetes were treated and followed for 30 months. RESULTS—Treatment improved symptoms in seven of nine patients. Exocrine and endocrine function assessed by fecal elastase and A1C were not affected, although fecal lipid excretion was reduced. Vitamin E was low in all patients but increased with treatment (P < 0.001 at 30 months) and improved in five subjects. A predominantly demyelinating neuropathy was seen in a majority of patients, and carpal tunnel syndrome was common. CONCLUSIONS—Pancreatic enzyme substitution alleviated symptoms and malabsorption and normalized vitamin E levels. Glycemic control was not significantly affected. The CEL syndrome seems associated with a demyelinating neuropathology. |
format | Text |
id | pubmed-2518335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-25183352009-09-01 Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations Vesterhus, Mette Ræder, Helge Aurlien, Harald Gjesdal, Clara G. Bredrup, Cecilie Holm, Pål I. Molven, Anders Bindoff, Laurence Berstad, Arnold Njølstad, Pål R. Diabetes Care Clinical Care/Education/Nutrition/Psychosocial Research OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL gene mutation, exocrine deficiency, and diabetes were treated and followed for 30 months. RESULTS—Treatment improved symptoms in seven of nine patients. Exocrine and endocrine function assessed by fecal elastase and A1C were not affected, although fecal lipid excretion was reduced. Vitamin E was low in all patients but increased with treatment (P < 0.001 at 30 months) and improved in five subjects. A predominantly demyelinating neuropathy was seen in a majority of patients, and carpal tunnel syndrome was common. CONCLUSIONS—Pancreatic enzyme substitution alleviated symptoms and malabsorption and normalized vitamin E levels. Glycemic control was not significantly affected. The CEL syndrome seems associated with a demyelinating neuropathology. American Diabetes Association 2008-09 /pmc/articles/PMC2518335/ /pubmed/18544793 http://dx.doi.org/10.2337/dc07-2217 Text en Copyright © 2008, DIABETES CARE Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Clinical Care/Education/Nutrition/Psychosocial Research Vesterhus, Mette Ræder, Helge Aurlien, Harald Gjesdal, Clara G. Bredrup, Cecilie Holm, Pål I. Molven, Anders Bindoff, Laurence Berstad, Arnold Njølstad, Pål R. Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title | Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title_full | Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title_fullStr | Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title_full_unstemmed | Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title_short | Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations |
title_sort | neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to cel mutations |
topic | Clinical Care/Education/Nutrition/Psychosocial Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518335/ https://www.ncbi.nlm.nih.gov/pubmed/18544793 http://dx.doi.org/10.2337/dc07-2217 |
work_keys_str_mv | AT vesterhusmette neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT ræderhelge neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT aurlienharald neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT gjesdalclarag neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT bredrupcecilie neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT holmpali neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT molvenanders neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT bindofflaurence neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT berstadarnold neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations AT njølstadpalr neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations |